ArticleACS omega2025
Cross-Linked Cyclodextrin-Based Nanoparticles as Drug Delivery Vehicles: Synthesis Strategy and Degradation Studies.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanoparticle-encapsulated hepcidin as a dietary strategy to improve growth, biochemical status, and immune responses in common carp (Veterinary and animal science · 2026Article
- Supramolecular Cyclodextrin Nanofibers for Active Food Preservation: Current Trends and Future Perspectives.Foods (Basel, Switzerland) · 2026Review
- Cyclodextrin-Grafted Polysaccharides as Sustainable Platforms for Biomedical and Environmental Applications.International journal of molecular sciences · 2026Review
- Advanced PMSSO Hydrogel Cross-Linked Cyclodextrin Composite Carrier for Enhanced Oral Delivery of Iron to Treat Anemia.Gels (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we report on the synthesis and characterization of cyclodextrin-based nanocarriers, intended as new biogenic and biodegradable drug-delivery agents. Specifically, β-cyclodextrins were covalently cross-linked by carbonyl linkages using carbonyldiimidazole (CDI) and were colloidally stabilized via PEGylation to form β-CD-CO-PEG nanoparticles termed CD-CO NPs. The optimized synthesis results in size-controlled nanoparticles with a narrow particle size distribution and a hydrodynamic diameter around 200-300 nm in water and 100-160 nm as dried powder as observed by scanning electron microscopy. CD-CO nanoparticles are promising drug delivery carriers as they offer an intrinsic pore system originating from the β-cyclodextrin building units and an additional intraparticle pore space created by cross-linking these β-cyclodextrin units. We demonstrate the biodegradability of these materials and show exemplarily their drug delivery potential using two different model cargos. Time-based fluorescence release measurements
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.